There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...

But a lot of the biggest presentations flowed out of the company’s partnership with Innovent Biologics that was announced ...

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart (SAR445088) in rare disease ...

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, adding to its ...

Bayer's oral Factor XIa inhibitor asundexian is now under regulatory review by the EMA for secondary prevention of ischaemic ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Rebecca Guntern, chief commercial officer at Sandoz, for ...

Parabilis Medicines is expecting to raise around $670 million in its public offering, with another $75 million in a ...

The FDA has broadened the label for Eli Lilly's anti-IL-13 antibody Ebglyss, approving a maintenance regimen for atopic dermatitis (eczema) that involves just six injections a year. After a period of ...

A survey has shown that UK doctors think AI can help them save time and expand their capacity to care for patients, but three ...

There was a similar picture in SYNCHRONIZE-MASLD, revealed for the first time at ADA and simultaneously published in Nature ...

Incyte has agreed to buy Star Therapeutics subsidiary Vega Therapeutics for $1.25 billion upfront, adding a late-stage drug ...

AI and connected data are reshaping feasibility and site selection across the clinical development lifecycle, allowing ...